Ovarian Cancer MedDRA version: 14.1 Level: PT Classification code 10066697 Term: Ovarian cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Sponsors
sanofi-aventis recherche & développement
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Signed informed consent. 2. At least 18 years of age. 3. Histological and/or cytological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, or primary peritoneal carcinoma. 4. Completion of maximum one previous line of chemotherapy containing a platinum agent. Neoadjuvant/adjuvant treatment that include a surgical procedure will be considered as one line if platinum-based. 5. Documented sensitivity to a platinum-based chemotherapy regimen. “Platinum-sensitivity” is defined by a radiologic relapse more than 6 months after last dose of platinum based chemotherapy. 6. Measurable progressive disease: Measurable disease (as defined by RECIST 1.1) is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be at least 10 mm³ when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be >15 mm in short axis when measured by CT or MRI. In case of a single measurable lesion, this should not be previously irradiated. 7. ECOG performance status =2 8. Life expectancy more than 12 weeks Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. History of uncontrolled brain metastases, spinal cord compression, or carcinomatous meningitis. 2. History of another neoplasm. Adequately treated basal cell or squamous skin cancer, or in situ cervical cancer, or any other cancer from which the patient has been disease-free for >5 years are allowed. 3. Participation in another clinical trial and any concurrent treatment with any investigational drug or anti-tumor therapy or radiotherapy within 21 days prior to randomization (or 28 days for those therapies with a schedule of administration every 4 weeks and except for nitrosoureas, mitomycin which may not be used up to 6 weeks prior to the first cycle provided that patients do not have residual signs of any toxicity). No wash-out is required for hormonotherapy which has to be discontinued before the first cycle. 4. Any severe acute or chronic medical condition, which could impair the ability of the patient to participate in the study or interfere with interpretation of study results. 5. Pregnancy or breast-feeding. Positive serum or urine pregnancy test prior to randomization. 6. Patient with reproductive potential who do not agree to use accepted and effective method of contraception during the study treatment period and for at least 6 months after the completion of the study treatment. The definition of “effective method of contraception” will be based on the investigator’s judgment. Effective method of contraception should also be adapted to local regulations. 7. Inadequate organ function including: neutrophils 2.5 times the upper normal limits of the institutional norms. An increase of AP up to grade 2 would be accepted only if this increase is related to the presence of bone metastases. Bone specific isoenzyme AP should be evaluated. 8. Urine protein-creatinin ratio (UPCR) >1 (urinanalysis on morning spot urine) or proteinuria >500 mg/24h 9. Pre-existing peripheral neuropathy > grade 1 according to the NCI CTCAE V.4.03 10. Pre-existing hearing impairment > grade 1 11. Known hypersensitivity due to taxanes and /or polysorbate 80 or any other compound/excipients of the study drug combination 12. Discontinuation of previous treatment with paclitaxel and/or carboplatin for toxicity reason 13. Other serious illness or medical conditions such as (but not restricted): - Active infection - Superior vena cava syndrome - Pericardial effusion requiring intervention (drainage) 14. Documented medical history of myocardial infarction, documented angina pectoris, arrhythmia especially severe conduction disorder such as second or third-degree atrioventricular block, stroke, or history of arterial or venous thrombo-embolism within the past 6 months still requiring anticoagulants. 15. Cardiac Troponin at levels that exceed the normal ranges values defined by the laboratory 16. Uncontrolled hypertension within 3 months prior to study treatment or patient with organ damage related to hypertension. 17. Patient with LVEF value lower than institution inferior normal limit, evaluated by echocardiography or angiocardiography 18. 12-lead ECG: - Infarction Q-wave, - ST segment depression or elevation =1 mm in at least 2 contiguous leads - QT/QTc-Time >450 ms
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To demonstrate an improvement in Progression-Free Survival (PFS) for ombrabulin versus placebo in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with paclitaxel and carboplatin.;Secondary Objective: - To compare the overall survival (OS) between the 2 treatment arms - To compare the objective response rate (RR) between the 2 treatment arms ;Primary end point(s): Progression Free Survival (PFS).;Timepoint(s) of evaluation of this end point: approximately 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Overall Surival (OS) Objective Response Rate (RR);Timepoint(s) of evaluation of this end point: approximately 24 months | — |
Countries
Belgium, Czech Republic, Germany, Italy, Poland, Russian Federation, Ukraine, United States
Contacts
Public ContactJean VAN RAMPELBERGH
sanofi-aventis Belgium
Outcome results
None listed